You searched for Cybin - Page 20 of 60

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces

Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label products Company’s involvement in functional, psychoactive mushrooms space is also gaining steam Pure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In January 2021, Cybin announced that it would be partnering with Kernel to leverage its proprietary Kernel Flow device for … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Upcoming Jefferies Virtual Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer Doug Drysdale will be presenting at the Jefferies Virtual Health Care Conference 2021. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Tuesday, June 1, 2021. Interested parties should visit https://ibn.fm/Dx6YF to … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Upcoming Jefferies Virtual Health Care Conference”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that further strengthens its psychedelic derivative drug development candidates across 153 global jurisdictions. Per the update, the application, governed by the Patent Cooperation Treaty (“PCT”), grants Cybin the right to file future … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries”

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, … Continue reading “Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio “

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently appointed Alexander Belser as its chief clinical officer and Aaron Bartlone to serve as chief operating officer. Belser and Bartlone bring a wealth of experience and will provide the company with added insight and expertise in … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Strengthens IP Portfolio with 12th Patent Filing

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by the company. In the announcement, the company noted that the application discloses novel compositions anticipated to have improved pharmacokinetic profiles … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Strengthens IP Portfolio with 12th Patent Filing”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation (“CYB001”) in a Phase II clinical trial for patients suffering with major … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder”

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update”

Site Search

Company Search

Search Results for: Cybin